Posted inNews and Updates
New EpiCrispr Gene Therapy Shows Promise for Muscle Growth
Discover how new EpiCrispr gene silencing technology is transforming muscular dystrophy treatment by promoting muscle growth without altering DNA.
Posted inNews and Updates
AI Chatbots Struggle with Surgical Accuracy: New Study
New research shows ChatGPT-5 provides overly optimistic projections for macular hole surgery, highlighting critical risks in relying on AI for medical advice.
Posted inNews and Updates
US Expands Access to Experimental Ebola Treatment
The US is rolling out a new experimental Ebola drug to boost outbreak response. Discover how this antiviral treatment aims to improve patient survival.
Posted inNews and Updates
First China-Approved CAR-T Therapy for Solid Tumors
A historic CAR-T approval for solid tumors and a $10B Pfizer-Innovent pact signal a new era of global oncology innovation and strategic biopharma growth.
Posted inNews and Updates
EU Regulators Recommend Jaypirca for Chronic Leukemia
The CHMP has recommended the approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia. Learn about this new BTK inhibitor therapy.
Posted inNews and Updates
Glaukos Hits Key Milestone in Phase II GLK-321 Eye Trial
Glaukos has completed patient enrollment for its Phase II clinical trial of GLK-321, marking a key milestone in developing new ophthalmic therapies.
Posted inNews and Updates
Generative AI in Primary Care: Does It Improve Outcomes?
New research explores the impact of Generative AI in primary care. Can AI-driven decision support improve patient outcomes and clinical efficiency?
Posted inNews and Updates
Bonsai Biotherapeutics Secures Green Light for Clinical Trial
Bonsai Biotherapeutics, backed by Flerie, has received clinical trial approval to advance its therapeutic pipeline into human safety and efficacy testing.
Posted inNews and Updates
US FDA Grants Tentative Approval to Lupin’s Enzalutamide
Lupin receives tentative US FDA approval for Enzalutamide tablets, a key treatment for prostate cancer. Learn what this means for oncology patients.
Posted inNews and Updates
ProQR Reports Positive AX-0810 Phase 1 Trial Results
ProQR’s AX-0810 shows promising Phase 1 results, confirming target engagement for treating cholestatic diseases. Learn about the trial's latest impact.